As previously

TM

(the “Agreement”) with Jefferies LLC (“Jefferies”), under which the Company may offer and sell, from time to time at its sole discretion through Jefferies, as its sales agent, its common shares, par value of CHF 0.03 per share (the “Common Shares”).

On December 11, 2020, the Company filed a prospectus supplement with the U.S. Securities and Exchange Commission (the “SEC”) to offer and sell from time to time at its sole discretion through Jefferies, as its sales agent, additional Common Shares having an aggregate offering price of up to $350,000,000 (the “Offering”). The Common Shares for the Offering will be offered and sold pursuant to the Company’s previously filed automatically effective shelf registration statement on

Form S-3 (File No. 333-227427) filed

by the Co mpany with the SEC on September 19, 2018.

The legal opinion of Walder Wyss AG relating to the legality of the issuance and sale of the Common Shares in the Offering is attached as Exhibit 5.1 to this Current Report on

Form 8-K. This

Current Report on

Form 8-K shall

not constitute an offer to sell or the solicitation of an offer to buy the securities discussed herein, nor shall there be any offer, solicitation, or sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

 




Item 9.01.


Financial Statements and Exhibits.

(d) Exhibits:

 








Exhibit

   No.   


  


Description






  5.1


  


Opinion of Walder Wyss AG.






23.1


  


Consent of Walder Wyss AG (included in Exhibit 5.1).






104


  


Cover Page Interactive Data File (embedded within the Inline XBRL document).







SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 













 



 


CRISPR THERAPEUTICS AG








Date: December 11, 2020


 



 


By:


 


/s/ Samarth Kulkarni




 



 



 


Samarth Kulkarni, Ph.D.




 



 



 


Chief Executive Officer






makes a similar move, sign up!

Other recent filings from the company include the following:

CRISPR Therapeutics AG's Chief Executive Officer just cashed-in 30,000 options - June 17, 2021
CRISPR Therapeutics AG director just disposed of 10,000 shares - June 15, 2021
CRISPR Therapeutics AG director was just granted 10,000 options - June 14, 2021
Amendments to Articles of Incorporation or - June 14, 2021
Statement of changes in beneficial ownership of securities - June 14, 2021

Auto Refresh

Feedback